Leukemia
Conditions
Keywords
chronic phase chronic myelogenous leukemia
Brief summary
RATIONALE: Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with imatinib in treating patients with previously treated chronic phase chronic myelogenous leukemia.
Detailed description
OBJECTIVES: Primary * To determine the safety and tolerability of LBH589 given in combination with imatinib mesylate in CML patients who are in Major Cytogenetic Remission (MCR) with residual BCR-ABL positive cells after at least 1 year of daily imatinib mesylate treatment. * To determine the maximum tolerated dose (MTD) and dose-limiting toxicity of LBH589 given in combination with imatinib mesylate in CML patients. Secondary * To study the effect of LBH589 given in combination with imatinib mesylate on cytogenetic response status and BCR-ABL levels in CML patients in major cytogenetic remission on imatinib mesylate treatment. Tertiary * To study the effect of LBH589 given in combination with imatinib mesylate on residual BCR-ABL positive primitive progenitors in CML patients in major cytogenetic remission on imatinib mesylate treatment. OUTLINE: This is dose-escalation study of panobinostat. Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
Interventions
DRUGimatinib mesylate
Given orally
DRUGpanobinostat
Given orally
GENETICpolymerase chain reaction
Testing
GENETICprotein expression analysis
Testing
GENETICwestern blotting
Testing
OTHERflow cytometry
Testing
OTHERlaboratory biomarker analysis
Testing
OTHERpharmacological study
Testing
Sponsors
National Cancer Institute (NCI)
City of Hope Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * CML CP patients who have been treated with and tolerated Imatinib for 1 year or more, have achieved at least major cytogenetic response and continue to be BCR-ABL positive (Patients should be receiving Imatinib at a dose of 400 daily at the time of entry into the study) * ANC and PLT need to be in the normal range * Serum albumin \>= 3g/dL * AST/SGOT and ALT/SGPT =\< 2.5 x upper limit of normal (ULN) * Serum bilirubin =\< 1.5 x ULN * Serum creatinine =\< 1.5 x ULN or 24-hour creatinine clearance \>= 50 ml/min * Serum potassium \>= lower limit of normal (LLN) * Serum phosphorus \>= LLN * Serum total calcium (corrected for serum albumin) or serum ionized calcium \>= LLN * Serum magnesium \>= LLN * ECOG performance status of =\< 2
Exclusion criteria
* Prior treatment with an HDAC inhibitor * Patient who have been treated with Imatinib \< 1 year or patients are currently being treated with Imatinib at a dose \> 400 mg daily * Impaired cardiac function including any one of the following: Screening ECG with a QTc \> 450 msec; Patients with congenital long QT syndrome; History or presence of sustained ventricular tachycardia; Any history of ventricular fibrillation or torsades de pointes; Bradycardia defined as heart rate \< 50 beats per minute (patients with a pacemaker and heart rate \>= 50 beats per minute are eligible); Patients with a myocardial infarction or unstable angina within 6 months of study entry; Congestive heart failure (NY Heart Association class III or IV); Right bundle branch block and left anterior hemiblock (bifascicular block) * Uncontrolled hypertension * Concomitant use of drugs with a risk of prolonging the QT interval or inducing torsades de pointes * Concomitant use of CYP3A4 inhibitors * Patients with unresolved diarrhea \> CTCAE grade 1 * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589 * Other concurrent severe and/or uncontrolled medical conditions * Patients who have received chemotherapy, any investigational drug or undergone major surgery \< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy * Concomitant use of any other anti-cancer therapy or radiation therapy * Patients being treated with Coumadin (unless patients who require anticoagulation can be switched to a low-molecular weight or standard heparin) * Female patients who are pregnant or breast feeding or patients of reproductive potential not willing to use a double method of contraception including a barrier method (i.e. condom) during the study and 3 months after the end of treatment (Women of childbearing potential \[WOCBP\] must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589) * Male patients whose sexual partners are WOCBP not willing to use a double method of contraception including condom during the study and 3 months after the end of treatment * Patients with a history of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin * Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required * Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose of histone deacetylase inhibitor LBH589 in combination with imatinib mesylate | 1 month |
| Safety and tolerability of histone deacetylase inhibitor LBH589 in combination with imatinib mesylate | 4 months |
Secondary
| Measure | Time frame |
|---|---|
| Effect of treatment with histone deacetylase inhibitor LBH589 in combination with imatinib mesylate on cytogenetic response status and BCR-Abl levels | 4 months |
| Effect of treatment with histone deacetylase inhibitor LBH589 in combination with imatinib mesylate on residual BCR-Abl positive primitive progenitors | 4 months |
Countries
United States
Outcome results
None listed